G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 166,700 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc.
February 1, 2022
· 2 min read
